<SEC-DOCUMENT>0001193125-19-051944.txt : 20190226
<SEC-HEADER>0001193125-19-051944.hdr.sgml : 20190226
<ACCEPTANCE-DATETIME>20190226161032
ACCESSION NUMBER:		0001193125-19-051944
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190226
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190226
DATE AS OF CHANGE:		20190226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HERON THERAPEUTICS, INC. /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33221
		FILM NUMBER:		19633476

	BUSINESS ADDRESS:	
		STREET 1:		4242 CAMPUS POINT COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8582514400

	MAIL ADDRESS:	
		STREET 1:		4242 CAMPUS POINT COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AP PHARMA INC /DE/
		DATE OF NAME CHANGE:	20010511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d712457d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): February&nbsp;26, 2019 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Heron Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-33221</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>94-2875566</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>4242 Campus Point Court, Suite 200, San Diego, CA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>92121</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code (858)
<FONT STYLE="white-space:nowrap">251-4400</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01 Other Events. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;26, 2019, Heron Therapeutics, Inc. (the &#147;Company&#148;) issued a press release announcing that the U.S. Food and Drug Administration has
approved the Company&#146;s Supplemental New Drug Application for CINVANTI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (aprepitant) injectable emulsion for administration as a <FONT STYLE="white-space:nowrap">2-minute</FONT>
intravenous injection, as described in the press release furnished herewith as Exhibit&nbsp;99.1. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d712457dex991.htm">Press Release, dated February&nbsp;26, 2019 </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Heron Therapeutics, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: February&nbsp;26, 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ David Szekeres</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David Szekeres</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Vice President, General Counsel,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Business Development and Corporate Secretary</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d712457dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g712457heron.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Heron Announces FDA Approval of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Supplemental New Drug Application to Expand CINVANTI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Label for IV Push </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SAN DIEGO, Calif.&#150; (PR NEWSWIRE) &#150; February&nbsp;26, 2019 &#150; Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company
focused on improving the lives of patients by developing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatments to address some of the most important unmet patient needs, today announced that the
U.S. Food and Drug Administration (FDA) has approved Heron&#146;s supplemental New Drug Application (sNDA) for CINVANTI (aprepitant) injectable emulsion, for intravenous (IV)&nbsp;use. The sNDA requested FDA approval to expand the administration of
CINVANTI beyond the already approved administration method (a <FONT STYLE="white-space:nowrap">30-minute</FONT> IV infusion) to include a <FONT STYLE="white-space:nowrap">2-minute</FONT> IV injection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CINVANTI is the first and only polysorbate <FONT STYLE="white-space:nowrap">80-free,</FONT> IV formulation of an NK<SUB
STYLE="font-size:85%; vertical-align:bottom">1 </SUB>receptor antagonist (RA) indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). CINVANTI is the first IV formulation to directly deliver aprepitant, the
active ingredient in EMEND<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP><SUP STYLE="font-size:85%; vertical-align:top"> </SUP>capsules. Aprepitant (including its prodrug, fosaprepitant) is the only single-agent NK<SUB
STYLE="font-size:85%; vertical-align:bottom">1 </SUB>RA to significantly reduce CINV in both the acute phase (0 &#150; 24 hours after chemotherapy) and the delayed phase (24 &#150; 120 hours after chemotherapy).</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CINVANTI was initially approved based on data demonstrating the bioequivalence of CINVANTI to EMEND
IV<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(fosaprepitant), supporting its efficacy for the prevention of acute and delayed CINV following highly emetogenic cancer chemotherapy (HEC) and moderately emetogenic cancer
chemotherapy (MEC). Results from two pivotal, randomized, cross-over, bioequivalence studies of CINVANTI and EMEND IV showed subjects receiving CINVANTI reported fewer adverse events than those receiving EMEND IV, including substantially fewer
infusion-site reactions.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The new method of administration for CINVANTI was approved based on a
third study demonstrating bioequivalence and a comparable safety profile for CINVANTI given as a <FONT STYLE="white-space:nowrap">30-minute</FONT> IV infusion and as a <FONT STYLE="white-space:nowrap">2-minute</FONT> IV injection, also referred to
as an IV push. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;CINVANTI, delivering the efficacy of aprepitant, but without polysorbate 80, has been an important addition for the prevention of
CINV. Notably, data now show that the <FONT STYLE="white-space:nowrap">2-minute</FONT> IV push has comparable safety to the <FONT STYLE="white-space:nowrap">30-minute</FONT> IV infusion. This approval will enable physicians to leverage the
operational advantages of this method of administration and will contribute to a reduction in total patient time spent in the infusion suite,&#148; said Rudolph M. Navari, M.D., Ph.D., University of Alabama, Birmingham School of Medicine, Division
of Hematology Oncology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are pleased to have strengthened our CINV franchise with today&#146;s label expansion for CINVANTI, as we now have the
only NK<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> RA that offers the benefits and flexibility of an IV push method of administration,&#148; said Barry Quart, Pharm.D., President and Chief Executive Officer of Heron.
&#147;Administration of CINVANTI by <FONT STYLE="white-space:nowrap">2-minute</FONT> IV push is an important advantage for our customers compared to EMEND IV, which requires reconstitution and an IV bag for infusion.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CINVANTI (aprepitant) injectable emulsion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with
initial and repeat courses of highly emetogenic cancer chemotherapy (HEC), including high-dose cisplatin, and nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g712457heron.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">chemotherapy (MEC). CINVANTI is an IV formulation of
aprepitant, a substance <FONT STYLE="white-space:nowrap">P/neurokinin-1</FONT> (NK<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>) receptor antagonist (RA). CINVANTI is the first IV formulation to directly deliver aprepitant, the active
ingredient in EMEND<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> capsules. Aprepitant (including its prodrug, fosaprepitant) is the only single-agent NK<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> RA to significantly reduce
nausea and vomiting in both the acute phase (0 &#150; 24 hours after chemotherapy) and the delayed phase (24 &#150; 120 hours after chemotherapy). CINVANTI is the only IV formulation of an NK<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>
RA indicated for the prevention of acute and delayed nausea and vomiting associated with HEC and nausea and vomiting associated with MEC that is free of polysorbate 80 or any other synthetic surfactant. The
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> dosing administration included in the United States prescribing information for CINVANTI is a <FONT STYLE="white-space:nowrap">30-minute</FONT> infusion or a
<FONT STYLE="white-space:nowrap">2-minute</FONT> injection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please see full prescribing information at <U>www.CINVANTI.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Safety Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contraindications
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CINVANTI is contraindicated in patients with hypersensitivity to any of the components of CINVANTI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent use of pimozide with CINVANTI is contraindicated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warnings and Precautions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinically Significant
CYP3A4 Drug Interactions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aprepitant is a substrate, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">weak-to-moderate</FONT></FONT>
(dose-dependent) inhibitor, and an inducer of CYP3A4. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Use with other drugs that are CYP3A4 substrates may result in increased plasma concentration of the concomitant
drug. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Use of pimozide with CINVANTI is contraindicated due to the risk of significantly increased plasma concentrations
of pimozide, potentially resulting in prolongation of the QT interval, a known adverse reaction of pimozide. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Use of CINVANTI with strong or moderate CYP3A4 inhibitors (e.g., ketoconazole, diltiazem) may increase plasma
concentrations of aprepitant and result in an increased risk of adverse reactions related to CINVANTI. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Use of CINVANTI with strong CYP3A4 inducers (e.g., rifampin) may result in a reduction in aprepitant plasma
concentrations and decreased efficacy of aprepitant. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Hypersensitivity Reactions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Serious hypersensitivity reactions, including anaphylaxis during or soon after administration of CINVANTI have occurred. Symptoms including dyspnea, eye
swelling, flushing, pruritus, and wheezing have been reported. If hypersensitivity reactions occur, discontinue CINVANTI. Do not reinstate CINVANTI in patients who experience these symptoms with previous use. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Decrease in INR with Concomitant Warfarin </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">Co-administration</FONT> of CINVANTI with warfarin, a CYP2C9 substrate, may result in a clinically significant decrease in the International Normalized Ratio (INR) of prothrombin time. Monitor the INR in patients on
chronic warfarin therapy in the <FONT STYLE="white-space:nowrap">2-week</FONT> period, particularly at 7 to 10 days, following initiation of CINVANTI with each chemotherapy cycle. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g712457heron.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Risk of Reduced Efficacy of Hormonal
Contraceptives </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The efficacy of hormonal contraceptives may be reduced during administration of and for 28 days following the last dose of CINVANTI.
Advise patients to use effective alternative or <FONT STYLE="white-space:nowrap">back-up</FONT> methods of <FONT STYLE="white-space:nowrap">non-hormonal</FONT> contraception during treatment with CINVANTI and for 1 month following administration of
CINVANTI or oral aprepitant, whichever is administered last. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use in Specific Populations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Avoid use of CINVANTI in pregnant women as alcohol is an inactive ingredient for CINVANTI. There is no safe level of alcohol exposure in pregnancy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Adverse Reactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The most common adverse reactions with
the <FONT STYLE="white-space:nowrap">3-day</FONT> oral aprepitant regimen in conjunction with MEC (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>1% and greater than standard therapy) were fatigue and eructation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The most common adverse reactions with the single-dose intravenous fosaprepitant regimen in conjunction with HEC were generally similar to that seen in prior
HEC studies with oral aprepitant. In addition, infusion site reactions (3%) occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The most common adverse reactions with single-dose CINVANTI (<FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>2%) were headache and fatigue. The safety profile of CINVANTI in healthy subjects who received a single <FONT STYLE="white-space:nowrap">2-minute</FONT> injection was similar to that seen with a <FONT
STYLE="white-space:nowrap">30-minute</FONT> infusion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Heron Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatments to address some of the most important unmet patient needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved
pharmacological agents for patients suffering from pain or cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, visit <U>www.herontx.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This news release contains
&#147;forward-looking statements&#148; as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management&#146;s expectations and assumptions as of the date of this news
release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to, those associated with: the commercial opportunity for CINVANTI IV push; and other risks and uncertainties
identified in the Company&#146;s filings with the U.S. Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be
required by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g712457heron.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Relations and Media Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David Szekeres </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior VP, General Counsel, Business
Development&nbsp;and Corporate Secretary </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heron Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">dszekeres@herontx.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">858-251-4447</FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>### </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g712457heron.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g712457heron.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MM2RWFRVCEU*;S/,XU)8R-%-PA4I*C"FZBVA>2:6R:/GG@?:XZ^88G&SIQP&
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MV_AJ-OB+;>,/M<@F@\%7GAH6'E)Y1CN-<L-4-V9MVX2*UH(]FW&')SD<_0O
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J%:K2Q?.H<L94O94H.G3=Y1DIRBYRO*/+:-K63EW/>:^J/>"@ H * /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
